Across TCGA pan-cancer cohorts, NHSL2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated NHSL2 data layer compared with 21 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher NHSL2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated NHSL2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and GBM show a favorable association.

CCRCC, LUAD, and GBM are the cancer types where NHSL2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	III,IV	0.904	0.529	.002	40	view →
LUAD	DFS	Median	III,IV	0.493	0.982	<.001	29	view →
GBM	OS	Median	All	0.633	0.420	.004	19	view →
PDAC	OS	Median	III,IV	0.896	0.591	.010	7	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: NHSL2 tumor-vs-normal RNA expression · all NHSL2 data types